Lu Hang, Cui Jinglin, Dong Hui, Luo Binjiang, Xiu Weiwei, Li Huimei
Department of Ophthalmology, the First Hospital of Qiqihar, Qiqihar 161000, Heilongjiang Province, China.
Department of Ophthalmology, the First Hospital of Qiqihar, Qiqihar 161000, Heilongjiang Province, China; Email:
Zhonghua Yan Ke Za Zhi. 2015 Nov;51(11):818-21.
To observe the efficacy and safety of intravitreal injection of conbercept, a new drugs of VEGFR fusion proteins, on wet age-related macular degeneration (wAMD).
To analyze retrospectively the clinical data of 58 patients with wet wAMD, which was diagnosed by examination of ETDRS charts, color fundus photograph, fluorescein angiography (FFA) and optical coherence tomography (OCT), were underwent intravitreal injection conbercept 0.5 mg (0.05 ml of 10 g/L). Follow-up time was 6 to 12 months.Visual acuity (ETDRS charts letter), retinal thickness, leakage of CNV and operative complications before and after the treatment were analyzed.
Conbercept injection therapeutic times were 3-5, the average therapeutic times were 3.05. At the end of the follow-up period, the mean letter of ETDRS charts was 50.20±12.87, increased 26.20 letters (t=2.936, P<0.01). the ETDRS charts improved 15 or more letters in 33 eyes (53.23%), decreased more than 15 letters in 2 eyes (3.23%); the average foveal thickness on OCT images were (223±74) µm after treatment, decreased significantly (t=3.669, P<0.01) ; FFA showed CNV complete closure in 34 eyes (54.84%), partial closure in 23 eyes (37.10%), no change in 5 eyes (8.06%). IOP increased in 2 eyes after treatment and recovered within one week.
Intravitreal injection of conbercept for wAMD was well tolerated, with an improvement in BCVA, macular edema and leakage of CNV, reduce the risk of rehaemorrhagia.
观察玻璃体内注射血管内皮生长因子受体（VEGFR）融合蛋白新药康柏西普治疗湿性年龄相关性黄斑变性（wAMD）的疗效及安全性。
回顾性分析58例经ETDRS视力表检查、彩色眼底照相、荧光素眼底血管造影（FFA）及光学相干断层扫描（OCT）确诊的湿性wAMD患者的临床资料，均接受玻璃体内注射0.5mg（0.05ml，10g/L）康柏西普治疗。随访时间为6至12个月。分析治疗前后的视力（ETDRS视力表字母）、视网膜厚度、脉络膜新生血管（CNV）渗漏情况及手术并发症。
康柏西普注射治疗次数为3至5次，平均治疗次数为3.05次。随访期末，ETDRS视力表平均字母数为50.20±12.87，提高了26.20个字母（t=2.936，P<0.01）。ETDRS视力表提高15个或更多字母的有33只眼（53.23%），降低超过15个字母的有2只眼（3.23%）；治疗后OCT图像上黄斑中心凹平均厚度为（223±74）μm，显著降低（t=3.669，P<0.01）；FFA显示CNV完全闭合34只眼（54.84%），部分闭合23只眼（37.10%），无变化5只眼（8.06%）。治疗后2只眼眼压升高，1周内恢复。
玻璃体内注射康柏西普治疗wAMD耐受性良好，可改善最佳矫正视力、黄斑水肿及CNV渗漏，降低再出血风险。
